secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cogent Biosciences, Inc. (COGT)
CIK:        0001622229
Form:       8-K
Filed at:   2024-02-14T23:59:59+00:00
Accession:  0001193125-24-035203
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 1.01, 5.03, 3.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cogent Biosciences raises $225M in oversubscribed PIPE at $7.50/share, 37% premium
--------------------------------------------------------------------------------

- Gross proceeds of $225M from 17.7M common shares at $7.50 and Series B convertible preferred.
- Pro-forma cash expected to fund into 2027 through SUMMIT, PEAK, and APEX registration trials.
- Led by Commodore Capital; includes Fairmount, Redmile, Janus, TCGX, Adage, Venrock, Deerfield, Perceptive.
- Investor webcast on Feb 23 to review SUMMIT Part 1b data at AAAAI annual meeting.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1622229/000119312524035203/0001193125-24-035203-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1622229/000119312524035203/d790187d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-035203

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer